ConclusionThus, even children receiving anti-cancer chemotherapy may have a mild or asymptomatic course of COVID-19. While we should not underestimate the risk of developing a more severe course of COVID-19 than observed here, the intensity of preventive measures should not cause delays or obstructions in oncological treatment.
change with same therapeutic target (SWITCH) and drug change with different therapeutic target (SWAP). The Studentś t test for correlated groups was performed but any intervention involving SWAP or SWITCH was excluded. Asymptomatic patients without altered APR and optimal plasma adalimumab concentrations maintained the same treatment scheme. Results 89 patients were analysed and 41 (46%) patients were proposed and accepted for interventions, of whom 22 (54%) were men with a mean age of 40 years (18-66). The data are shown in table 1. Interventions performed: 21 (51%) deintensification, 10 (24%) intensification, 7 (17%) SWAP and 3 (7%) SWITCH. Symptomatic patients before interventions totalled 19 (46%); after the interventions 4 (10%) patients remained symptomatic, 3 after intensification and 1 after a treatment SWITCH. Conclusion and relevance APR improved after interventions. Faecal calprotectin showed a significative p value. Further studies are required. Monitoring adalimumab along with clinical patient data is crucial to optimise IBD control. This practice is effective, safe and contributes to the sustainability of the health system, saving possible adverse effects and money. Clinical pharmacists have a crucial role in optimal clinical patient development.
change with same therapeutic target (SWITCH) and drug change with different therapeutic target (SWAP). The Studentś t test for correlated groups was performed but any intervention involving SWAP or SWITCH was excluded. Asymptomatic patients without altered APR and optimal plasma adalimumab concentrations maintained the same treatment scheme. Results 89 patients were analysed and 41 (46%) patients were proposed and accepted for interventions, of whom 22 (54%) were men with a mean age of 40 years (18-66). The data are shown in table 1. Interventions performed: 21 (51%) deintensification, 10 (24%) intensification, 7 (17%) SWAP and 3 (7%) SWITCH. Symptomatic patients before interventions totalled 19 (46%); after the interventions 4 (10%) patients remained symptomatic, 3 after intensification and 1 after a treatment SWITCH. Conclusion and relevance APR improved after interventions. Faecal calprotectin showed a significative p value. Further studies are required. Monitoring adalimumab along with clinical patient data is crucial to optimise IBD control. This practice is effective, safe and contributes to the sustainability of the health system, saving possible adverse effects and money. Clinical pharmacists have a crucial role in optimal clinical patient development.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.